{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T15:43:18Z","timestamp":1786203798059,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018935","name":"Universit\u00e4tsklinikum Erlangen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018935","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background\/Purpose<\/jats:title>\n                    <jats:p>A subset of psoriasis (PsO) patients exhibits subclinical entheseal inflammation and bone remodeling placing them at higher risk of developing psoriatic arthritis (PsA). Whether early pharmacological interventions during this phase can modulate these inflammatory and structural changes remains largely unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this single-arm, open-label trial (EPos, EUDRACT 2018-000335-27) PsO patients with moderate-to-severe psoriasis, arthralgia, subclinical inflammatory and\/or structural bone changes assessed by hand MRI and\/or HR-pQCT were included. Patients who had current or past signs of PsA or prior b\/tsDMARD exposure were excluded. Participants received apremilast 30 mg BID over 24 weeks. The primary endpoint was the change in structural entheseal lesions (SEL) (number, density and structure) at hand joints assessed by HR-pQCT (week 24). Secondary endpoints were change in bone and inflammatory alterations assessed by MRI (PsAMRIS) as well as clinical response.Safety was monitored<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty patients (50.0\u00b111.6 years;9 women) were included, all with long-standing PsO and frequent nail and scalp involvement. Over 24 weeks no significant progression in the SEL number was detected while entheseal cortical density and cortical thickness also remained stable. No progression in number and volume of erosions was observed. Total PsAMRIS as marker of inflammation remained stable. Significant improvements in skin disease activity (PASI: 10.9\u00b16.7 vs. 5.2\u00b16.6,p=0.013) and tender joint count (3.2\u00b13.4 vs. 0.8\u00b11.8,p=0.006) was seen. No new safety signals emerged.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In PsO patients at increased risk of PsA, no significant change in subclinical entheseal bone or inflammatory imaging was observed over 24 weeks of apremilast treatment, while skin disease activity and pain outcomes improved. These findings support further investigation of disease-interception strategies in early psoriatic disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-026-03873-z","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T02:26:39Z","timestamp":1786155999000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of apremilast on entheseal bone damage in psoriasis patients at risk of developing psoriatic arthritis - data from the prospective, interventional EPOS study"],"prefix":"10.1186","volume":"28","author":[{"given":"David","family":"Simon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Minopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Bayat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koray","family":"Tascilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Roemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melek Yalcin","family":"Mutlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Rech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Kr\u00f6nke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Fagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sticherling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Schett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2026-7728","authenticated-orcid":false,"given":"Arnd","family":"Kleyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,8]]},"reference":[{"issue":"10","key":"3873_CR1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic Arthritis. N Engl J Med. 2017;376(10):957\u201370.","journal-title":"N Engl J Med"},{"issue":"3","key":"3873_CR2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41584-019-0175-0","volume":"15","author":"JU Scher","year":"2019","unstructured":"Scher JU, Ogdie A, Merola JF, Ritchlin C. Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. Nat Rev Rheumatol. 2019;15(3):153\u201366.","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"3873_CR3","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/art.41239","volume":"74","author":"D Simon","year":"2022","unstructured":"Simon D, Tascilar K, Kleyer A, Bayat S, Kampylafka E, Sokolova MV, et al. Association of Structural Entheseal Lesions With an Increased Risk of Progression From Psoriasis to Psoriatic Arthritis. Arthritis Rheumatol. 2022;74(2):253\u201362.","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"3873_CR4","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1136\/annrheumdis-2015-208821","volume":"75","author":"F Faustini","year":"2016","unstructured":"Faustini F, Simon D, Oliveira I, Kleyer A, Haschka J, Englbrecht M, et al. Subclinical joint inflammation in patients with psoriasis without concomitant psoriatic arthritis: a cross-sectional and longitudinal analysis. Ann Rheum Dis. 2016;75(12):2068\u201374.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"3873_CR5","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1136\/annrheumdis-2014-206347","volume":"75","author":"D Simon","year":"2016","unstructured":"Simon D, Faustini F, Kleyer A, Haschka J, Englbrecht M, Kraus S, et al. Analysis of periarticular bone changes in patients with cutaneous psoriasis without associated psoriatic arthritis. Ann Rheum Dis. 2016;75(4):660\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"3873_CR6","doi-asserted-by":"publisher","first-page":"e001067","DOI":"10.1136\/rmdopen-2019-001067","volume":"5","author":"A Zabotti","year":"2019","unstructured":"Zabotti A, McGonagle DG, Giovannini I, Errichetti E, Zuliani F, Zanetti A, et al. Transition phase towards psoriatic arthritis: clinical and ultrasonographic characterisation of psoriatic arthralgia. RMD Open. 2019;5(2):e001067\u2013e.","journal-title":"RMD Open"},{"issue":"10","key":"3873_CR7","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/s41584-023-01016-1","volume":"19","author":"I Minopoulou","year":"2023","unstructured":"Minopoulou I, Kleyer A, Yalcin-Mutlu M, Fagni F, Kemenes S, Schmidkonz C, et al. Imaging in inflammatory arthritis: progress towards precision medicine. Nat Rev Rheumatol. 2023;19(10):650\u201365.","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"3873_CR8","doi-asserted-by":"publisher","first-page":"e001067","DOI":"10.1136\/rmdopen-2019-001067","volume":"5","author":"A Zabotti","year":"2019","unstructured":"Zabotti A, McGonagle DG, Giovannini I, Errichetti E, Zuliani F, Zanetti A, et al. Transition phase towards psoriatic arthritis: clinical and ultrasonographic characterisation of psoriatic arthralgia. RMD Open. 2019;5(2):e001067.","journal-title":"RMD Open"},{"issue":"1","key":"3873_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41590-025-02351-z","volume":"27","author":"MG Raimondo","year":"2026","unstructured":"Raimondo MG, Mohammadian H, Angeli MR, Alivernini S, Fedorchenko V, Huang K, et al. Skin-derived myeloid precursors and joint-resident fibroblasts spread psoriatic disease from skin to joints. Nat Immunol. 2026;27(1):35\u201347.","journal-title":"Nat Immunol"},{"issue":"8","key":"3873_CR10","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1002\/art.22758","volume":"56","author":"D McGonagle","year":"2007","unstructured":"McGonagle D, Lories RJ, Tan AL, Benjamin M. The concept of a synovio-entheseal complex and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. Arthritis Rheum. 2007;56(8):2482\u201391.","journal-title":"Arthritis Rheum"},{"key":"3873_CR11","doi-asserted-by":"crossref","unstructured":"Gra\u00dfhoff H, Comd\u00fchr S, Nording H, von Esebeck J, Letz P, Prohaczka M, et al. Transition from psoriasis to psoriatic arthritis is characterized by distinct alterations in peripheral blood Tc17, Th17 and CD4\u2009+\u2009TEM cells. Arthritis Rheumatol. 2025;78(2):332\u201343.","DOI":"10.1002\/art.43396"},{"issue":"6","key":"3873_CR12","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/s41584-022-00776-6","volume":"18","author":"G Schett","year":"2022","unstructured":"Schett G, Rahman P, Ritchlin C, McInnes IB, Elewaut D, Scher JU. Psoriatic arthritis from a mechanistic perspective. Nat Rev Rheumatol. 2022;18(6):311\u201325.","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"3873_CR13","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1136\/ard-2023-224148","volume":"82","author":"A Zabotti","year":"2023","unstructured":"Zabotti A, De Marco G, Gossec L, Baraliakos X, Aletaha D, Iagnocco A, et al. EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis. Ann Rheum Dis. 2023;82(9):1162.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"3873_CR14","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1136\/ard-2023-224148","volume":"82","author":"A Zabotti","year":"2023","unstructured":"Zabotti A, De Marco G, Gossec L, Baraliakos X, Aletaha D, Iagnocco A, et al. EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis. Ann Rheum Dis. 2023;82(9):1162\u201370.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3873_CR15","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1136\/annrheumdis-2021-219961","volume":"81","author":"P Gisondi","year":"2022","unstructured":"Gisondi P, Bellinato F, Targher G, Idolazzi L, Girolomoni G. Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. Ann Rheum Dis. 2022;81(1):68\u201373.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3873_CR16","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1136\/annrheumdis-2021-220865","volume":"81","author":"ML Acosta Felquer","year":"2022","unstructured":"Acosta Felquer ML, LoGiudice L, Galimberti ML, Rosa J, Mazzuoccolo L, Soriano ER. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis. Ann Rheum Dis. 2022;81(1):74\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"3873_CR17","doi-asserted-by":"publisher","first-page":"e200","DOI":"10.1016\/S2665-9913(23)00034-6","volume":"5","author":"S Singla","year":"2023","unstructured":"Singla S, Putman M, Liew J, Gordon K. Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study. Lancet Rheumatol. 2023;5(4):e200\u20137.","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"3873_CR18","doi-asserted-by":"publisher","first-page":"257","DOI":"10.55563\/clinexprheumatol\/8thj0l","volume":"38","author":"D Solmaz","year":"2020","unstructured":"Solmaz D, Ehlebracht A, Karsh J, Bakirci S, McGonagle D, Aydin SZ. Evidence that systemic therapies for psoriasis may reduce psoriatic arthritis occurrence. Clin Exp Rheumatol. 2020;38(2):257\u201361.","journal-title":"Clin Exp Rheumatol"},{"key":"3873_CR19","doi-asserted-by":"crossref","unstructured":"Rosenthal YS, Schwartz N, Sagy I, Pavlovsky L. Incidence of Psoriatic Arthritis Among Patients Receiving Biologic Treatments for Psoriasis: A Nested Case-Control Study. Arthritis & Rheumatology (Hoboken, NJ). 2022;74(2):237\u201343.","DOI":"10.1002\/art.41946"},{"issue":"1","key":"3873_CR20","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13075-019-1957-0","volume":"21","author":"E Kampylafka","year":"2019","unstructured":"Kampylafka E, Simon D, d\u2019Oliveira I, Linz C, Lerchen V, Englbrecht M, et al. Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation-data from the prospective IVEPSA study. Arthritis Res Ther. 2019;21(1):178.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"3873_CR21","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s40744-024-00680-3","volume":"11","author":"A Watad","year":"2024","unstructured":"Watad A, Zabotti A, Patt YS, Gendelman O, Dotan A, Ben-Shabat N, et al. From Psoriasis to Psoriatic Arthritis: Decoding the Impact of Treatment Modalities on the Prevention of Psoriatic Arthritis. Rheumatol Therapy. 2024;11(4):963\u201376.","journal-title":"Rheumatol Therapy"},{"issue":"5","key":"3873_CR22","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1136\/annrheumdis-2017-211568","volume":"77","author":"P Nash","year":"2018","unstructured":"Nash P, Ohson K, Walsh J, Delev N, Nguyen D, Teng L, et al. Early and sustained efficacy with apremilast monotherapy in biological-na\u00efve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE). Ann Rheum Dis. 2018;77(5):690\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"3873_CR23","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","volume":"73","author":"A Kavanaugh","year":"2014","unstructured":"Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73(6):1020\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"3873_CR24","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665\u201373.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"3873_CR25","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1136\/ard.2007.084244","volume":"68","author":"WP Maksymowych","year":"2009","unstructured":"Maksymowych WP, Mallon C, Morrow S, Shojania K, Olszynski WP, Wong RL, et al. Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index. Ann Rheum Dis. 2009;68(6):948\u201353.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"3873_CR26","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/art.23568","volume":"59","author":"PJ Healy","year":"2008","unstructured":"Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum. 2008;59(5):686\u201391.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"3873_CR27","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1136\/ard.62.2.127","volume":"62","author":"L Heuft-Dorenbosch","year":"2003","unstructured":"Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, Landew\u00e9 R, van ver Tempel H, Mielants H, et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis. 2003;62(2):127\u201332.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"3873_CR28","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1002\/jbmr.3025","volume":"32","author":"D Simon","year":"2017","unstructured":"Simon D, Kleyer A, Stemmler F, Simon C, Berlin A, Hueber AJ, et al. Age- and Sex-Dependent Changes of Intra-articular Cortical and Trabecular Bone Structure and the Effects of Rheumatoid Arthritis. J Bone Min Res. 2017;32(4):722\u201330.","journal-title":"J Bone Min Res"},{"key":"3873_CR29","doi-asserted-by":"publisher","first-page":"850552","DOI":"10.3389\/fmed.2022.850552","volume":"9","author":"L Folle","year":"2022","unstructured":"Folle L, Simon D, Tascilar K, Kr\u00f6nke G, Liphardt AM, Maier A, et al. Deep Learning-Based Classification of Inflammatory Arthritis by Identification of Joint Shape Patterns-How Neural Networks Can Tell Us Where to Deep Dive Clinically. Front Med (Lausanne). 2022;9:850552.","journal-title":"Front Med (Lausanne)"},{"key":"3873_CR30","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.bone.2018.07.017","volume":"116","author":"D Simon","year":"2018","unstructured":"Simon D, Kleyer A, Englbrecht M, Stemmler F, Simon C, Berlin A, et al. A comparative analysis of articular bone in large cohort of patients with chronic inflammatory diseases of the joints, the gut and the skin. Bone. 2018;116:87\u201393.","journal-title":"Bone"},{"issue":"7","key":"3873_CR31","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1136\/annrheumdis-2017-212404","volume":"77","author":"F Stemmler","year":"2018","unstructured":"Stemmler F, Simon D, Liphardt AM, Englbrecht M, Rech J, Hueber AJ, et al. Biomechanical properties of bone are impaired in patients with ACPA-positive rheumatoid arthritis and associated with the occurrence of fractures. Ann Rheum Dis. 2018;77(7):973\u201380.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"3873_CR32","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.3899\/jrheum.090352","volume":"36","author":"M Ostergaard","year":"2009","unstructured":"Ostergaard M, McQueen F, Wiell C, Bird P, B\u00f8yesen P, Ejbjerg B, et al. The OMERACT psoriatic arthritis magnetic resonance imaging scoring system (PsAMRIS): definitions of key pathologies, suggested MRI sequences, and preliminary scoring system for PsA Hands. J Rheumatol. 2009;36(8):1816\u201324.","journal-title":"J Rheumatol"},{"issue":"8","key":"3873_CR33","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.3899\/jrheum.090352","volume":"36","author":"M \u00d8Stergaard","year":"2009","unstructured":"\u00d8Stergaard M, McQueen F, Wiell C, Bird P, B\u00d8Yesen P, Ejbjerg BO, et al. The OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Scoring System (PsAMRIS): Definitions of Key Pathologies, Suggested MRI Sequences, and Preliminary Scoring System for PsA Hands. J Rhuematol. 2009;36(8):1816.","journal-title":"J Rhuematol"},{"issue":"1","key":"3873_CR34","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13075-019-1938-3","volume":"21","author":"D Simon","year":"2019","unstructured":"Simon D, Kleyer A, Bayat S, Tascilar K, Kampylafka E, Meinderink T, et al. Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients. Arthritis Res Ther. 2019;21(1):162.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"3873_CR35","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1136\/annrheumdis-2013-204858","volume":"74","author":"M Haroon","year":"2015","unstructured":"Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6\u2005months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015;74(6):1045\u201350.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3873_CR36","doi-asserted-by":"publisher","first-page":"e004062","DOI":"10.1136\/rmdopen-2023-004062","volume":"10","author":"SVJ Snoeck Henkemans","year":"2024","unstructured":"Snoeck Henkemans SVJ, de Jong PHP, Luime JJ, Kok MR, Tchetverikov I, Korswagen L-A, et al. Window of opportunity in psoriatic arthritis: the earlier the better? RMD Open. 2024;10(1):e004062.","journal-title":"RMD Open"},{"issue":"11","key":"3873_CR37","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1136\/annrheumdis-2021-220263","volume":"80","author":"JS Smolen","year":"2021","unstructured":"Smolen JS, Siebert S, Korotaeva TV, Selmi C, Bergmans P, Gremese E, et al. Effectiveness of IL-12\/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results. Ann Rheum Dis. 2021;80(11):1419\u201328.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"3873_CR38","doi-asserted-by":"publisher","first-page":"e063650","DOI":"10.1136\/bmjopen-2022-063650","volume":"12","author":"RH Haberman","year":"2022","unstructured":"Haberman RH, MacFarlane KA, Catron S, Samuels J, Blank RB, Toprover M, et al. Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial. BMJ Open. 2022;12(12):e063650.","journal-title":"BMJ Open"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-026-03873-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-026-03873-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-026-03873-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T15:02:08Z","timestamp":1786201328000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13075-026-03873-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,8]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3873"],"URL":"https:\/\/doi.org\/10.1186\/s13075-026-03873-z","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,8]]},"assertion":[{"value":"20 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the local ethics commission and by the Federal Institute for Drugs and Medical Devices (Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte) and was conducted at the University Hospital of Erlangen in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants prior to study enrollment.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients gave written consent before entering the trial.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DS has served on scientific advisory boards for AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen-Cilag, Lilly, Novartis, UCB; received speaker honoraria from AbbVie, Amgen, Alfasigma, Bristol-Myers Squibb, Janssen-Cilag, Lilly, Novartis, UCB. AK scientific advisory boards UCB, Lilly, Novartis, Alfasigma and speaker honoraria from AbbVie, Amgen, Alfasigma, Bristol-Myers Squibb, Janssen-Cilag, Lilly, Novartis, UCB. FWR is CMO, Director or Research and shareholder of Boston Imaging Core lab (BICL), LLC., a company providing image assessment services for academia and the pharmaceutical industry. JR has served on scientific advisory boards for Novartis, Sobi and speaker honoraria from Novartis, Sobi, BMS. FF received speaking honoraria, travel reimbursement, and research support from Janssen-Cilag, Lilly, Novartis, AstraZeneca, UCB, Novartis.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"149"}}